| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Regular Articles |
Transgenic Mice
From the Department of Pathobiological Sciences,* School of Veterinary Medicine, and the Department of Pathology and Laboratory Medicine, School of Medicine, University of Wisconsin–Madison, Madison, Wisconsin
Whey acidic protein (WAP)-transforming growth factor (TGF)-
transgenic mice acquire both cancerous and noncancerous mammary lesions. For this study, we evaluated the effect of mouse strain background on the incidence, latency, and histotype of two noncancerous lesions, hyperplastic alveolar nodules (analogous to typical hyperplasias in women), and macrocysts. These lesions display characteristics of fibrocystic changes observed in breasts of women, and in both mice and humans are associated with an uncertain risk of progression to neoplasia. Virgin transgenic mice of the (C57BL/6J;SJL)F2 background developed very few hyperplastic alveolar nodules and no macrocysts. In contrast, when the WAP-TGF- transgene was carried on the FVB/N strain, congenic virgin transgenic mice acquired both lesion types with 
100% penetrance. In the (FVB;C57BL/6J)F1 background, hyperplastic alveolar nodule incidence was reduced to approximately the nontransgenic mouse level, and macrocyst latency was increased dramatically. Crossing into C57BL/6 resulted in elimination of the macrocyst phenotype. Finally, FVB strain transgenic mammary epithelium transplanted into nontransgenic recipients of the FVB/N or (FVB;C57BL/6J)F1 backgrounds displayed macrocyst latency characteristic of the recipient, and not donor, mouse strain. Quantitative real-time polymerase chain reaction analysis demonstrated that, despite the difference in macrocyst incidence between (FVB;C57BL/6J)F1 and C57BL/6 virgin transgenic mice (81% versus 0%), the level of TGF- expression was not different. FVB strain transgenic mice expressed only twofold more TGF- than the other backgrounds. These findings indicate that C57BL/6J modifier alleles inhibit mammary lesion incidence and macrocyst latency in a semidominant manner, and that suppression of lesion development can involve host factors that are independent of mammary epithelial genotype.
This article has been cited by other articles:
 |
|
 |
|
  A. C. Blackburn, L. Z. Hill, A. L. Roberts, J. Wang, D. Aud, J. Jung, T. Nikolcheva, J. Allard, G. Peltz, C. N. Otis, et al. Genetic Mapping in Mice Identifies DMBT1 as a Candidate Modifier of Mammary Tumors and Breast Cancer Risk Am. J. Pathol., June 1, 2007; 170(6): 2030 - 2041. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. M. Arendt, T. A. Rose-Hellekant, E. P. Sandgren, and L. A. Schuler Prolactin Potentiates Transforming Growth Factor {alpha} Induction of Mammary Neoplasia in Transgenic Mice Am. J. Pathol., April 1, 2006; 168(4): 1365 - 1374. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. D. Woodworth, E. Michael, L. Smith, K. Vijayachandra, A. Glick, H. Hennings, and S. H. Yuspa Strain-dependent differences in malignant conversion of mouse skin tumors is an inherent property of the epidermal keratinocyte Carcinogenesis, September 1, 2004; 25(9): 1771 - 1778. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. R. Baldwin, N. A. Timchenko, and C. A. Zahnow Epidermal Growth Factor Receptor Stimulation Activates the RNA Binding Protein CUG-BP1 and Increases Expression of C/EBP{beta}-LIP in Mammary Epithelial Cells Mol. Cell. Biol., May 1, 2004; 24(9): 3682 - 3691. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. R. Tessier, G. A. Doyle, B. A. Clark, H. C. Pitot, and J. Ross Mammary Tumor Induction in Transgenic Mice Expressing an RNA-Binding Protein Cancer Res., January 1, 2004; 64(1): 209 - 214. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. P. Piechocki, Y.-S. Ho, S. Pilon, and W.-Z. Wei Human ErbB-2 (Her-2) Transgenic Mice: A Model System for Testing Her-2 Based Vaccines J. Immunol., December 1, 2003; 171(11): 5787 - 5794. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
